Your browser doesn't support javascript.
loading
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Urbonas, V; Schadendorf, D; Zimmer, L; Danson, S; Marshall, E; Corrie, P; Wheater, M; Plummer, E; Mauch, C; Scudder, C; Goff, M; Love, S B; Mohammed, S B; Middleton, M R.
Afiliação
  • Urbonas V; Early Phase Clinical Trials Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; National Cancer Institute, Vilnius, Lithuania.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, West German Cancer Centre, University Duisburg-Essen, Essen, Germany; The German Cancer Consortium, Essen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, West German Cancer Centre, University Duisburg-Essen, Essen, Germany; The German Cancer Consortium, Essen, Germany.
  • Danson S; Department of Oncology, Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UK.
  • Marshall E; Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK.
  • Corrie P; Department of Oncology, Addenbrookes Hospital, Cambridge, UK.
  • Wheater M; Department of Oncology, Southampton General Hospital, Southampton, UK.
  • Plummer E; Department of Oncology, Freeman Hospital, Newcastle upon Tyne, UK.
  • Mauch C; Köln Universitätsklinik, Köln, Germany.
  • Scudder C; Oncology Clinical Trials Office, University of Oxford, Oxford, UK.
  • Goff M; Oncology Clinical Trials Office, University of Oxford, Oxford, UK.
  • Love SB; Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
  • Mohammed SB; Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
  • Middleton MR; Early Phase Clinical Trials Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Oncology, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Electronic address: mark.middleton@oncology.ox.ac.uk.
Ann Oncol ; 30(2): 317-324, 2019 02 01.
Article em En | MEDLINE | ID: mdl-30428063
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Lituânia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Lituânia